Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABVC with free AI briefings, catalyst countdowns, and dilution alerts.

ABVC · ABVC BIOPHARMA, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.5M Cash, Pro Forma
30.6mo Cash Runway
Follow ABVC by email Get an email when ABVC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABVC, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Radix Polygalae Extract PDC-1421 Attention-Deficit Hyperactivity Disorder (ADHD) Phase 2 · NCT05202327 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABVC had $94,526 in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $3.5M pro forma, before operating spending after that date:

It burns about $341,662/quarter from operations, an estimated runway of 30.6 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 47 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABVC files for a raise →

👥 Who Owns ABVC

Insiders Form 4 data not loaded yet Other 5%+ holders 0.5% Institutions (15 holders) 4.7% Public and other holders 94.8%
HolderTypeShares% of sharesAs of
Eugene Jiang 5%+ holder (13D) 131,159 0.49% 2025-07-10

Share count 26,976,625 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ABVC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABVC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.